Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors

Inclusion Criteria: * signed informed consent. * Age 18-75. * life expectancy ≥3 months. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Subjects with histologically or cytologically confirmed advanced or metastatic solid tumors, unresponsive to standard treatment or for whom no standard treatment is available or appropriate. * The sequencing of the tumor was qualified. * Subject must have measurable diseases as per RECIST v1.1 criteria. * According to the investigator's judgment, venous vascular conditions can meet the needs of apheresis. * Adequate bone marrow, renal, and hepatic at screening and at Baseline. Exclusion Criteria: * Patients who have received therapeutic tumor vaccine products (including peptide vaccine, mRNA vaccine, DC vaccine, etc.). * Diagnosis of malignant diseases other than study disease within 5 years before screening (except for malignant tumors that can be expected to recover after treatment). * Patients received systemic antitumor treatment within 2 weeks before the apheresis, or receive research drugs or device therapy. * Received radiotherapy within 4 weeks prior to screening. * Toxicity caused by previous treatment did not recover to CTCAE (version 5.0) Grade 1 or below (except hair loss and peripheral neuropathy). * Patients who have active brain metastases or cancerous meningitis. * History of significant cardiovascular and cerebrovascular disease occurred in the 6 months prior to screening, Any of the following cardiac criteria: * Mean resting corrected QT interval (QTc) \> 470 ms; * Left ventricular ejection fraction (LVEF) ≤ 50%; * American New York heart association (NYHA) heart function ≥ 2 or higher; * serious arrhythmia; * poorly controlled hypertension; * other serious heart diseases; * Patients with interstitial pneumonia, except those inactive and do not require hormone therapy disease; * Any of the following test results are positive: human immunodeficiency virus (HIV) antibody, treponema pallidum antibody, hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg), HBV DNA and novel coronavirus nucleic acid. * Active tuberculosis (TB) during screening. * Treatment with systemic steroids or other immunosuppressive agents within 14 days prior to screening; * Vaccination within 4 weeks prior to screening. * Major injuries and/or surgery =\< 4 weeks prior to screening. * Persons with a history of psychotropic substance abuse and inability to abstain or with a history of mental disorders. * Pregnant or lactating women. * Other conditions are regimented at the investigators' discretion.